NBIX - Neurocrine settles all patent disputes related to movement disorder therapy
2023-11-13 13:23:47 ET
More on Neurocrine Biosciences
- Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript
- Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success
- Neurocrine reports Phase 2 study failures for two drug candidates
- Neurocrine Biosciences Q3 2023 Earnings Preview
For further details see:
Neurocrine settles all patent disputes related to movement disorder therapy